受强制性开放获取政策约束的文章 - Jayesh Desai了解详情
无法在其他位置公开访问的文章：9 篇
The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity
J Canon, K Rex, AY Saiki, C Mohr, K Cooke, D Bagal, K Gaida, T Holt, ...
Nature 575 (7781), 217-223, 2019
强制性开放获取政策： US Department of Energy, US National Institutes of Health, Howard Hughes …
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ...
The Lancet 394 (10197), 478-487, 2019
强制性开放获取政策： US National Institutes of Health
Survival impact of the Australian national bowel cancer screening programme
S Ananda, H Wong, I Faragher, IT Jones, M Steele, S Kosmider, J Desai, ...
Internal medicine journal 46 (2), 166-171, 2016
强制性开放获取政策： National Health and Medical Research Council, Australia
A Malignant Neoplasm From the Jejunum With a MALAT1-GLI1 Fusion and 26-Year Survival History
OWJ Prall, CRE McEvoy, DJ Byrne, A Iravani, J Browning, DYH Choong, ...
International journal of surgical pathology 28 (5), 553-562, 2020
强制性开放获取政策： US National Institutes of Health, National Health and Medical Research …
Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF-and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomized phase II ICECREAM study
JD Shapiro, S Thavaneswaran, CR Underhill, KP Robledo, CS Karapetis, ...
Clinical colorectal cancer 17 (4), 313-319, 2018
强制性开放获取政策： National Health and Medical Research Council, Australia
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis
A Shahnam, U Nindra, J Desai, R Hui, M Buyse, AM Hopkins, MJ Sorich
JNCI: Journal of the National Cancer Institute 115 (12), 1475-1482, 2023
强制性开放获取政策： National Health and Medical Research Council, Australia
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
J Liu, M Farrow, L Seymour, J Desai, HH Loong, P Ivy, T Koyoma, N Cook, ...
Journal of Clinical Oncology, JCO-24-01534, 2025
强制性开放获取政策： Cancer Research UK
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery
K Smith, S O'Haire, B Markman, HK Gan, K O'Byrne, M Millward, B Tran, ...
JCO Precision Oncology 8, e2300247, 2024
强制性开放获取政策： National Health and Medical Research Council, Australia
What is the future potential of the PI3K pathway in colorectal cancer treatment?
M Palmieri, J Desai, O Sieber
Colorectal Cancer 3 (2), 113-116, 2014
强制性开放获取政策： National Health and Medical Research Council, Australia
可在其他位置公开访问的文章：68 篇
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
强制性开放获取政策： US National Institutes of Health
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
DS Hong, MG Fakih, JH Strickler, J Desai, GA Durm, GI Shapiro, ...
New England Journal of Medicine 383 (13), 1207-1217, 2020
强制性开放获取政策： US National Institutes of Health, Damon Runyon Cancer Research Foundation …
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ...
Science translational medicine 8 (346), 346ra92-346ra92, 2016
强制性开放获取政策： US National Institutes of Health
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
B Tran, S Kopetz, J Tie, P Gibbs, ZQ Jiang, CH Lieu, A Agarwal, DM Maru, ...
Cancer 117 (20), 4623-4632, 2011
强制性开放获取政策： US National Institutes of Health
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
S Kopetz, J Desai, E Chan, JR Hecht, PJ O'Dwyer, D Maru, V Morris, ...
Journal of clinical oncology 33 (34), 4032-4038, 2015
强制性开放获取政策： US National Institutes of Health
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, ...
Annals of Oncology 26 (8), 1715-1722, 2015
强制性开放获取政策： US National Institutes of Health
Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer
RN Jorissen, P Gibbs, M Christie, S Prakash, L Lipton, J Desai, D Kerr, ...
Clinical Cancer Research 15 (24), 7642-7651, 2009
强制性开放获取政策： US National Institutes of Health
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and …
J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ...
Journal of Clinical Oncology 39 (4), 273-284, 2021
强制性开放获取政策： US National Institutes of Health
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer
NI Fleming, RN Jorissen, D Mouradov, M Christie, A Sakthianandeswaren, ...
Cancer research 73 (2), 725-735, 2013
强制性开放获取政策： National Health and Medical Research Council, Australia
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
M Mao, F Tian, JM Mariadason, CC Tsao, R Lemos Jr, F Dayyani, ...
Clinical cancer research 19 (3), 657-667, 2013
强制性开放获取政策： US National Institutes of Health
Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
J Goldstein, B Tran, J Ensor, P Gibbs, HL Wong, SF Wong, E Vilar, J Tie, ...
Annals of Oncology 25 (5), 1032-1038, 2014
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定